Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10816772 | 0.89 | CA12 (0.73) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4618261 | 0.86 | SFRP1 (0.62) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL13554193 | 0.84 | ALDH1A1 (0.56) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL18972371 | 0.84 | ALDH1A1 (0.56) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL1348425 | 0.84 | TSHR (0.73) | NPSR1TSHRALDH1A1CA12CA2 | |
| SCHEMBL6130639 | 0.84 | CA12 (0.81) | NPSR1TSHRALDH1A1LMNACA12 | |
| SCHEMBL19068937 | 0.83 | ALDH1A1 (0.56) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL10694347 | 0.82 | ALDH1A1 (0.69) | NPSR1TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3971066 | 0.82 | TSHR (0.66) | NPSR1TSHRALDH1A1CA12CA2 | |
| SCHEMBL7028080 | 0.82 | TSHR (0.71) | NPSR1TSHRALDH1A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| EP-1831183-A1 | 1,6-SUBSTITUTED (3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | claimed |
| EP-1341760-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | claimed |
| WO-2002036564-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | claimed |
| CN-119591526-A | High-polarity quaternary ammonium salt antibacterial agent and preparation method thereof | 苏州华道生物药业股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119490438-A | Water-soluble quaternary ammonium salt antibacterial agent and preparation method thereof | 苏州华道生物药业股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119490439-A | Preparation method of arylsulfonyl amino quaternary ammonium salt antibacterial agent | 苏州华道生物药业股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2022032223-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002036564-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| EP-0093765-A4 | 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-04-27 | — | — | EP | disclosed |
| EP-0093765-A1 | 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-11-16 | — | — | EP | disclosed |
| WO-1983001770-A1 | 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | NPSR1 399/4885TSHR 2355/4885ALDH1A1 4236/4885 |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | NPSR1 1951/4885TSHR 3811/4885ALDH1A1 1242/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | NPSR1 1951/4885TSHR 3811/4885ALDH1A1 1242/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | NPSR1 2321/4885TSHR 3870/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.